Mercilon

Desogestrel and Ethinylestradiol, the active ingredients in Mercilon, are a combined oral contraceptive presented as a 0.15 mg/0.02 mg tablet for oral use. It is prescribed to prevent pregnancy and to help regulate the menstrual cycle in women of reproductive age.

GNH USA supplies Mercilon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mercilon, a combined oral contraceptive, is indicated for hormonal regulation of the reproductive system.

Prevention of pregnancy: provides reliable contraceptive protection for women of reproductive age. Menstrual cycle regulation: helps achieve more predictable bleeding patterns. Treatment of moderate acne: improves skin lesions associated with hormonal fluctuations.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or soreness. - Spotting between periods: irregular light bleeding. - Mood changes: irritability or emotional fluctuations. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Pulmonary embolism: clot migration to lungs. - Stroke: cerebrovascular accident, especially in high‑risk women. - Myocardial infarction: heart attack in susceptible individuals. - Severe hypertension: sudden rise in blood pressure. - Liver tumor: rare hepatic adenoma development.

Before prescribing Mercilon, clinicians should assess individual risk factors and contraindications.

Pregnancy contraindication: must not be used during pregnancy. Smoking in women >35 years: avoid due to increased cardiovascular risk. History of thromboembolism: contraindicated because of clot risk. Uncontrolled hypertension: may exacerbate blood pressure. Severe liver disease: impaired metabolism can increase drug levels. Store at ambient temperature: keep in the original pack, protect from moisture.

Mercilon may interact with several medicines that alter its effectiveness or safety.

Major Interactions (Avoid): - Rifampin, phenytoin, carbamazepine: enzyme inducers that reduce contraceptive efficacy. - Ritonavir, other protease inhibitors: may increase hormone levels, raising clot risk. - St. John's wort: herbal inducer that lowers plasma concentrations. - Certain antifungals (ketoconazole): can increase hormone levels, heightening side‑effect risk.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): may modestly affect hormone metabolism. - Antihypertensives: oral contraceptives can reduce blood‑pressure control. - Diuretics: may increase risk of electrolyte imbalance. - Anticonvulsants (e.g., valproate): may require dosage adjustment. - Ginseng: possible mild reduction in contraceptive effect.